AstraZeneca gets CDSCO nod to market cancer drug Imfinzi for additional indication

AstraZeneca Pharma India has secured approval from India's drug regulator for Durvalumab, marketed as Imfinzi. This new indication allows its use in treating advanced or recurrent endometrial cancer. The drug will be administered in combination with other therapies for initial treatment. Following this, Durvalumab will be used as maintenance therapy for specific patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kXT7w6P
via IFTTT